1
|
Jost S, Chang J, Rands K, Tomezsko P, Doyle E, Daillere R, Dudek T, Vrbanac V, Allen T, Tager A, Altfeld M. Impact of NK cells on control of HIV infection in humanized BLT mice (P6207). The Journal of Immunology 2013. [DOI: 10.4049/jimmunol.190.supp.118.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Evidence suggests natural killer (NK) cells can mediate antiviral activity in HIV-infected humans. Here, we sought to investigate whether the level of NK cell activation in primary HIV infection not only influences the NK cell mediated elimination of HIV infected cells, but also affects the longevity and effectiveness of HIV-specific T cell responses. To address this hypothesis, we monitored HIV viral loads and HIV-specific adaptive immune responses in a humanized BLT mouse model of HIV infection, comparing NK cell-depleted and control mice. Depletion was achieved through the use of an anti-NKp46 antibody prior to HIV infection. Proportions of immune cell subsets and viremia were assessed at baseline and then once a week for at least 5 weeks post-infection using flow cytometry and qRT-PCR. We observed that the impact of NK cells on plasma viral loads varied between batches of mice reconstituted with different tissues. One set of NK cell depleted mice displayed a 4-fold increase in viremia as well as decreased levels of T cell immune activation at 3 weeks post-infection. In a second group of mice reconstituted with independent human tissue, NK cell depletion had no significant effect on viral loads. These results suggest that further investigation is warranted to identify factors accounting for an increased control of HIV replication associated with NK cells in some individuals and not others, such as expression of a protective combination of KIR and HLA alleles.
Collapse
Affiliation(s)
| | - Judy Chang
- 1Ragon Institute of MGH, MIT and Harvard, Boston, MA
| | - Keith Rands
- 1Ragon Institute of MGH, MIT and Harvard, Boston, MA
| | | | - Erin Doyle
- 1Ragon Institute of MGH, MIT and Harvard, Boston, MA
| | | | - Timothy Dudek
- 1Ragon Institute of MGH, MIT and Harvard, Boston, MA
| | - Vladimir Vrbanac
- 2Center for Immunology and Inflammatory Diseases, Massachusetts Gen. Hosp., Boston, MA
| | - Todd Allen
- 1Ragon Institute of MGH, MIT and Harvard, Boston, MA
| | - Andrew Tager
- 2Center for Immunology and Inflammatory Diseases, Massachusetts Gen. Hosp., Boston, MA
- 1Ragon Institute of MGH, MIT and Harvard, Boston, MA
| | | |
Collapse
|
2
|
Chang J, Lindsay RJ, Doyle EH, Vrbanac V, Seung EN, Dudek T, Bosch RJ, Precopio M, Kandimalla E, Tager A, Altfeld M. TLR7/9 antagonist reduces HIV-1-induced immune activation. Retrovirology 2012. [PMCID: PMC3441975 DOI: 10.1186/1742-4690-9-s2-p172] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
3
|
Deruaz M, Murooka TT, Dudek T, Vrbanac VD, Tivet T, Bankert KC, Allen TM, Tager AM, Luster AD. The humanized BLT mouse to study HIV transmission. Retrovirology 2012. [PMCID: PMC3441807 DOI: 10.1186/1742-4690-9-s2-p197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
4
|
Chang JJ, Lindsay R, Doyle E, Vrbanac V, Seung E, Dudek T, Precopio M, Kandimalla E, Tager A, Altfeld M. Modification of immune activation in HIV-1-infected humanized mouse model using TLR7/9 antagonists (113.19). The Journal of Immunology 2012. [DOI: 10.4049/jimmunol.188.supp.113.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Background: T cell immune activation is a strong predictor of HIV-1 disease progression, and IFNα production following TLR7 stimulation has been associated with elevated CD8+ T cell activation. We hypothesize that modulation of TLR7 stimulation could be used to manipulate IFNα production and subsequently reduce HIV-1-associated immune activation. Methods: Humanized BLT mice were generated by transplanting irradiated NOD/SCID/IL2Rγc-/- mice with human fetal thymus, liver tissue and human hematopoietic stem cells. After immune reconstitution, human DC, monocyte and T cell populations were detectable in the mice, and in vitro TLR responsiveness of DCs and monocytes reflected those observed in human PBMCs. Humanized mice were infected with HIV-1 and then treated with a TLR7/9 antagonist. The T cell activation markers were examined at each stage by flow cytometry. Results: BLT mice-derived human pDC responses to TLR7 stimulation were significantly blocked by in vitro treatment with the TLR7/9 antagonist (P<0.05). HIV-1 infection of BLT mice led to increased expression of immune activation marker CD38 on human T cells in vivo, and treatment of infected mice with the TLR7/9 antagonist led to a significant reduction in CD38 expression. Conclusion: Treatment of HIV-1-infected humanized BLT mice with TLR7/9 antagonist resulted in significant reduction of HIV-1-associated immune activation, indicating an important role of the TLR7/9 pathway in mediating immune activation in HIV-1.
Collapse
Affiliation(s)
- J. Judy Chang
- 1Ragon Institute of MIT, MGH and Harvard, Harvard Med. Sch., Boston, MA
| | - Robert Lindsay
- 1Ragon Institute of MIT, MGH and Harvard, Harvard Med. Sch., Boston, MA
| | - Erin Doyle
- 1Ragon Institute of MIT, MGH and Harvard, Harvard Med. Sch., Boston, MA
| | - Vladimir Vrbanac
- 2Rheumatology, Allergy and Immunology Division, Massachusetts General Hospital, Boston, MA
| | - Edward Seung
- 2Rheumatology, Allergy and Immunology Division, Massachusetts General Hospital, Boston, MA
| | - Timothy Dudek
- 2Rheumatology, Allergy and Immunology Division, Massachusetts General Hospital, Boston, MA
| | - Melissa Precopio
- 3Idera Pharmaceuticals, Inc., Idera Pharmaceuticals, Inc., Cambridge, MA
| | - Ekambar Kandimalla
- 3Idera Pharmaceuticals, Inc., Idera Pharmaceuticals, Inc., Cambridge, MA
| | - Andrew Tager
- 2Rheumatology, Allergy and Immunology Division, Massachusetts General Hospital, Boston, MA
| | - Marcus Altfeld
- 1Ragon Institute of MIT, MGH and Harvard, Harvard Med. Sch., Boston, MA
| |
Collapse
|
5
|
Seung E, Dudek T, Dugast AS, Mattoo H, Vrbanac V, Tivey T, Cariappa A, Pillai S, Luster A, Tager A. Neutralizing anti-HIV antibodies develop in a humanized mouse model of HIV-1 infection (105.8). The Journal of Immunology 2012. [DOI: 10.4049/jimmunol.188.supp.105.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
In BLT (bone marrow-liver-thymus) humanized mice, human thymocytes are educated by autologous human thymic tissue, resulting in functional human T cells. In contrast, limitations to B cell maturation have been noted. But despite this, we show for the first time that HIV infected BLT mice can produce class-switched anti-HIV antibodies with neutralizing activities. Human transitional B cells were present in greater frequencies in BLT mice than adult humans. Most of these cells had a T1 phenotype in the blood and spleen. But despite this B cell maturation defect, class-switched IgG Abs against various HIV proteins were detected by Western Blot in HIV-infected BLT mice. Using ELISA to determine anti-p24 IgG Ab titers, Abs were present as early as 8 weeks post infection (p.i.), with peak Ab titers seen after 15 weeks. One infected mouse demonstrated a peak titer similar to that seen in a chronically infected human. Finally, plasma samples from infected BLT mice after 22 weeks p.i. demonstrated neutralizing activities against the challenge virus. IC50 neutralizing titers in these mice were greater than those from humans infected for up to 5 months, but less than one infected for several years. The ability of humanized BLT mice to generate functional humoral immune responses may be further improved by strategies to improve their B cell maturation, which will further improve the potential of these mice to become a model system to study candidate HIV vaccines and therapies.
Collapse
Affiliation(s)
- Edward Seung
- 1Center for Immunology and Inflammatory Diseases, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| | - Timothy Dudek
- 2Ragon Institute, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| | - Anne-Sophie Dugast
- 2Ragon Institute, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| | - Hamid Mattoo
- 3Cancer Center, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| | - Vladimir Vrbanac
- 1Center for Immunology and Inflammatory Diseases, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| | - Trevor Tivey
- 1Center for Immunology and Inflammatory Diseases, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| | - Annaiah Cariappa
- 3Cancer Center, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| | - Shiv Pillai
- 3Cancer Center, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| | - Andrew Luster
- 1Center for Immunology and Inflammatory Diseases, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| | - Andrew Tager
- 1Center for Immunology and Inflammatory Diseases, Massachusetts Gen. Hosp., Havard Med. Sch., Charlestown, MA
| |
Collapse
|
6
|
Reszka NJ, Dudek T, Knipe DM. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 2010; 28:2754-62. [PMID: 20117270 DOI: 10.1016/j.vaccine.2010.01.030] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2009] [Revised: 01/14/2010] [Accepted: 01/15/2010] [Indexed: 12/24/2022]
Abstract
The replication-defective herpes simplex virus 2 (HSV-2) dl5-29 mutant virus strain with deletions in the U(L)5 and U(L)29 genes has been shown to protect mice and guinea pigs against challenge with wild-type (wt) HSV-2 and to protect against ocular disease caused by HSV-1 infection. The dl5-29 strain is currently being prepared for clinical trials as a herpes vaccine candidate. As a possible approach to improve the efficacy of dl5-29 as a genital herpes vaccine, we replaced the U(L)41 gene encoding the virion host shutoff function (vhs) with the U(L)41 gene from HSV-1. While the HSV-2 U(L)41 and HSV-1 U(L)41 gene products have analogous functions, vhs-1 is 40-fold less active than vhs-2. Previously, it was shown that disruption of the U(L)41 gene can increase the efficacy of dl5-29 as a vaccine against HSV-2. These properties led us to hypothesize that replacement of vhs-2 by vhs-1 would decrease cytopathic effects in infected host cells, allowing longer survival of antigen-presenting cells and induction of stronger immune responses. The new recombinant dl5-29-41.1 virus shows nearly the same immunogenicity and protection against HSV-2 challenge as the parental dl5-29 virus or a triply deleted mutant virus, dl5-29-41, in the murine model of infection, and grows to higher titers than the parental strain in complementing cells, which is important for GMP production. The results have implications for the design of future HSV-2 vaccine candidates and mechanisms of induction of protective immunity against genital herpes.
Collapse
Affiliation(s)
- Natalia J Reszka
- Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
| | | | | |
Collapse
|
7
|
Boutwell CL, Schneidewind A, Brumme Z, Brockman M, Streeck H, Brumme C, Dudek T, Kane K, Kemper M, Walker B, Altfeld M, Allen T. P09-19 LB. CTL escape mutations in gag epitopes restricted by protective HLA class I alleles cause substantial reductions in viral replication capacity. Retrovirology 2009. [PMCID: PMC2767913 DOI: 10.1186/1742-4690-6-s3-p399] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
8
|
Liu X, Broberg E, Watanabe D, Dudek T, Deluca N, Knipe DM. Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine 2009; 27:2760-7. [PMID: 19428888 DOI: 10.1016/j.vaccine.2009.03.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2009] [Accepted: 03/02/2009] [Indexed: 01/08/2023]
Abstract
The herpes simplex virus 1 (HSV-1) d106 mutant virus is a multiple immediate-early gene deletion mutant virus that has been effective as an AIDS vaccine vector in rhesus macaques (Kaur A, Sanford HB, Garry D, Lang S, Klumpp SA, Watanabe D, et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 2007;357:199-214). Further analysis of this vector is needed to advance development into clinical trials. In this study we have defined the precise nature of the multiple IE gene mutations in the d106 viral genome and have used this information to construct a new transfer plasmid for gene transfer into d106. We tested the effect of an additional mutation in the U(L)41 gene on d106 immunogenicity and found that it did not improve the efficacy of the d106 vector, in contrast with results from other studies with U(L)41 gene mutants. The safety profile of d106 was improved by generating a new vector strain, d106S, with increased sensitivity to acyclovir. Finally, we have constructed a d106S recombinant vector that expresses the HIV clade C envelope protein. The d106S HIVenvC recombinant has retained the sensitivity to acyclovir, indicating that this phenotype is a stable property of the d106S vector.
Collapse
Affiliation(s)
- Xueqiao Liu
- Harvard Medical School, Department of Microbiology and Molecular Genetics, 200 Longwood Avenue, Boston, MA 02115, United States
| | | | | | | | | | | |
Collapse
|
9
|
Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 2008; 26:4034-40. [PMID: 18565628 DOI: 10.1016/j.vaccine.2008.05.022] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2008] [Revised: 05/02/2008] [Accepted: 05/09/2008] [Indexed: 10/22/2022]
Abstract
A replication-defective herpes simplex virus (HSV)-2 vaccine, dl5-29, which is deleted for two essential early genes, UL5 and UL29, is highly immunogenic and protective in mice and guinea pigs. In a prior study, a derivative of HSV-2 dl5-29 termed dl5-29-41L, which has an additional deletion in UL41 (that encodes the virion-host shut-off protein), was more immunogenic and protective against challenge with wild-type HSV-2 in mice when compared with dl5-29. To determine if deletion of UL41 improves the efficacy of dl5-29 in protecting guinea pigs from HSV-2, animals were immunized with dl5-29, dl5-29-41L, or PBS. The geometric mean neutralizing antibody titers from the dl5-29 and dl5-29-41L recipients were comparable (10(1.97) and 10(2.19), respectively, p=0.15). After intravaginal challenge with wild-type HSV-2, the dl5-29-41L and dl5-29 recipients shed similar titers of HSV-2 from the vagina. Mean acute disease severity scores, numbers of recurrences during 3 months after infection, and latent viral loads in sacral ganglia were similar for dl5-29 and dl5-29-41L (all p values >0.05). dl5-29 and dl5-29-41L completely protected mice from lethal challenge with HSV-2 and induced virus-specific CD8(+) T cells in the spleens of the animals. Thus, dl5-29 was as immunogenic and protective as dl5-29-41L under these conditions. dl5-29 was at least 250,000-fold less virulent than parental virus by intracranial inoculation in healthy mice, and caused no disease in SCID mice. Both dl5-29-41L and dl5-29 are equally effective and immunogenic in guinea pigs, and dl5-29 is very safe in immunocompromised animals.
Collapse
Affiliation(s)
- Yo Hoshino
- Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Da'Dara AA, Lautsch N, Dudek T, Novitsky V, Lee TH, Essex M, Harn DA. Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice. Vaccine 2006; 24:5211-9. [PMID: 16675073 DOI: 10.1016/j.vaccine.2006.03.078] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2006] [Revised: 03/21/2006] [Accepted: 03/24/2006] [Indexed: 10/24/2022]
Abstract
A number of HIV-1 vaccines are in various phases of clinical trials and many more are in the developmental pipeline. Vaccines are especially needed for developing countries where morbidity and mortality due to HIV/AIDS is most severe, the prevalence of HIV infection is highest, and its incidence is often still rising dramatically. Individuals living in these regions are often infected with one or more helminth parasites which systemically bias the immune system towards Th2-type as well as drive immune anergy. The goal of this study was to develop a multi-T-cell epitope DNA-based vaccine for HIV-1 subtype C and to determine the impact of helminth infection on the immune response to this vaccine. We found that vaccination of naïve mice with the multi-epitope vaccine, designated TD158, induced a strong HIV-1C-specific T-cell immune response, and that the addition of the Igkappa leader sequence to the TD158 vaccine construct significantly increased the frequencies of IFN-gamma secreting CD8+ T cells. However, the TD158 vaccine specific response of mice infected with the human helminth Schistosoma mansoni was significantly suppressed. The impact of schistosome infection on suppressing the virus-specific immune response was the same whether mice were vaccinated with the TD158 vaccine or with the Igkappa enhanced TD158. The results of this study suggest that helminth infection may pose a serious problem for vaccination with the DNA-based HIV-1 vaccine in developing country populations, and that the prevalence of helminth infections in the vaccine cohorts should be taken into account for HIV-1 vaccine trial design.
Collapse
Affiliation(s)
- Akram A Da'Dara
- Department of Immunology and Infectious Diseases, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA.
| | | | | | | | | | | | | |
Collapse
|
11
|
Wang WK, Lee CN, Dudek T, Chang SY, Zhao YJ, Essex M, Lee TH. Interaction between HIV type 1 glycoprotein 120 and CXCR4 coreceptor involves a highly conserved arginine residue in hypervariable region 3. AIDS Res Hum Retroviruses 2000; 16:1821-9. [PMID: 11118068 DOI: 10.1089/08892220050195784] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
Abstract
Several seven-transmembrane chemokine receptors are known to function as entry coreceptors for human immunodeficiency virus type 1. CCR5 and CXCR4 are the major coreceptors for non-syncytium-inducing (NSI) and syncytium-inducing (SI) viruses, respectively. During the natural course of infection, the emergence of variants with a phenotypic transition from NSI to SI and rapid disease progression is associated with expanded coreceptor usage to CXCR4. Characteristic amino acids at several positions in the hypervariable region 3 (V3) of gp120 have been linked to CXCR4 utilization. Previously, we reported that a highly conserved arginine residue of V3 played an important role in CCR5 utilization. In this study, the possible involvement of the same arginine residue in CXCR4 utilization was investigated. Amino acid substitutions introduced to this arginine on R5X4 viruses were found to have a significant effect on their utilization of CXCR4. These results, taken together with those reported previously, suggest that this highly conserved arginine may contribute to the functional convergence of chemokine coreceptor utilization by human immunodeficiency viruses and may represent a unique target for future antiviral design.
Collapse
Affiliation(s)
- W K Wang
- Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA
| | | | | | | | | | | | | |
Collapse
|
12
|
Wang WK, Dudek T, Essex M, Lee TH. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc Natl Acad Sci U S A 1999; 96:4558-62. [PMID: 10200301 PMCID: PMC16371 DOI: 10.1073/pnas.96.8.4558] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Crystallographic characterization of a ternary complex containing a monomeric gp120 core, parts of CD4, and a mAb, revealed a region that bridges the inner and outer domains of gp120. In a related genetic study, several residues conserved among primate lentiviruses were found to play important roles in CC-chemokine receptor 5 (CCR5) coreceptor utilization, and all but one were mapped to the bridging domain. To reconcile this finding with previous reports that the hypervariable region 3 (V3) of gp120 plays an important role in chemokine coreceptor utilization, elucidating the roles of various V3 residues in this critical part of the HIV type 1 (HIV-1) life cycle is essential. Alanine-scanning mutagenesis was carried out to identify V3 residues critical for CCR5 utilization. Our findings demonstrated that several residues in V3 were critical to CCR5 utilization. Furthermore, these residues included not only those conserved across HIV-1 subtypes, but also those that varied among HIV-1 subtypes. Although the highly conserved V3 residues may represent unique targets for antiviral designs, the involvement of variable residues raises the possibility that antigenic variation in the coreceptor binding domain could further complicate HIV-1 vaccine design.
Collapse
Affiliation(s)
- W K Wang
- Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115, USA
| | | | | | | |
Collapse
|
13
|
Wang WK, Dudek T, Zhao YJ, Brumblay HG, Essex M, Lee TH. CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120. Proc Natl Acad Sci U S A 1998; 95:5740-5. [PMID: 9576954 PMCID: PMC20449 DOI: 10.1073/pnas.95.10.5740] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The seven-transmembrane CCR5 was recently found to double as a coreceptor for a genetically diverse family of human and nonhuman primate lentiviruses. Paradoxically, the main region of the envelope protein believed to be involved in CCR5 utilization was mapped to hypervariable region 3, or V3, of the envelope glycoprotein gp120. In this study, we addressed the question of whether functional convergence in CCR5 utilization is mediated by certain V3 residues that are highly conserved among HIV type 1 (HIV-1), HIV type 2, and simian immunodeficiency virus. Site-directed mutagenesis carried out on three such V3 residues revealed that the Arg-298 of HIV-1 gp120 has an important role in CCR5 utilization. In contrast, no effect was observed for the other residues we tested. The inability of Arg-298 mutants to use CCR5 was not attributed to global alteration of gp120 conformation. Neither the expression, processing, and incorporation of mutant envelope proteins into virions, nor CD4 binding were significantly affected by the mutations. This interpretation is further supported by the finding that alanine substitutions of five residues immediately adjacent to the arginine residue had no effect on CCR5 utilization. Taken together, our data strongly suggests that the highly conserved Arg-298 residue identified in the V3 of HIV-1 has a significant role in CCR5 utilization, and may represent an unusually conserved target for future anti-viral designs.
Collapse
Affiliation(s)
- W K Wang
- Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115, USA
| | | | | | | | | | | |
Collapse
|